- Home
- SCM vs RCKT Comparison
SCM vs RCKT Comparison
Compare SCM & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCM
- RCKT
- Stock Information
- Founded
- SCM 2012
- RCKT 1999
- Country
- SCM United States
- RCKT United States
- Employees
- SCM N/A
- RCKT N/A
- Industry
- SCM Finance/Investors Services
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- SCM Finance
- RCKT Health Care
- Exchange
- SCM Nasdaq
- RCKT Nasdaq
- Market Cap
- SCM 397.8M
- RCKT 328.6M
- IPO Year
- SCM 2012
- RCKT N/A
- Fundamental
- Price
- SCM $12.24
- RCKT $3.85
- Analyst Decision
- SCM Hold
- RCKT Buy
- Analyst Count
- SCM 1
- RCKT 13
- Target Price
- SCM $13.00
- RCKT $12.88
- AVG Volume (30 Days)
- SCM 232.2K
- RCKT 3.1M
- Earning Date
- SCM 11-06-2025
- RCKT 11-03-2025
- Dividend Yield
- SCM 13.07%
- RCKT N/A
- EPS Growth
- SCM 11.71
- RCKT N/A
- EPS
- SCM 1.43
- RCKT N/A
- Revenue
- SCM $102,761,445.00
- RCKT N/A
- Revenue This Year
- SCM N/A
- RCKT N/A
- Revenue Next Year
- SCM $1.23
- RCKT $3,582.16
- P/E Ratio
- SCM $8.53
- RCKT N/A
- Revenue Growth
- SCM N/A
- RCKT N/A
- 52 Week Low
- SCM $11.19
- RCKT $2.19
- 52 Week High
- SCM $15.56
- RCKT $18.17
- Technical
- Relative Strength Index (RSI)
- SCM 38.63
- RCKT 55.13
- Support Level
- SCM $12.01
- RCKT $3.67
- Resistance Level
- SCM $12.37
- RCKT $4.06
- Average True Range (ATR)
- SCM 0.29
- RCKT 0.26
- MACD
- SCM 0.08
- RCKT -0.00
- Stochastic Oscillator
- SCM 54.32
- RCKT 39.57
About SCM Stellus Capital Investment Corporation
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.